NASDAQ:KRYS - Krystal Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.71 -0.97 (-4.47 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$20.71
Today's Range$20.51 - $22.66
52-Week Range$8.03 - $24.89
Volume53,661 shs
Average Volume130,636 shs
Market Capitalization$313.25 million
P/E Ratio-13.99
Dividend YieldN/A
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Current SymbolNASDAQ:KRYS
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio27.65
Quick Ratio27.65


Trailing P/E Ratio-13.99
Forward P/E Ratio-20.71
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.62 per share
Price / Book5.72


EPS (Most Recent Fiscal Year)($1.48)
Net Income$-7,920,000.00
Net MarginsN/A
Return on Equity-17.92%
Return on Assets-17.56%


Outstanding Shares14,430,000
Market Cap$313.25 million
OptionableNot Optionable

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

How were Krystal Biotech's earnings last quarter?

Krystal Biotech Inc (NASDAQ:KRYS) posted its quarterly earnings results on Monday, November, 5th. The company reported ($0.26) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.26). View Krystal Biotech's Earnings History.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Krystal Biotech.

What price target have analysts set for KRYS?

5 brokerages have issued twelve-month price targets for Krystal Biotech's stock. Their predictions range from $32.00 to $38.00. On average, they anticipate Krystal Biotech's stock price to reach $35.00 in the next year. This suggests a possible upside of 69.0% from the stock's current price. View Analyst Price Targets for Krystal Biotech.

What is the consensus analysts' recommendation for Krystal Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.

What are Wall Street analysts saying about Krystal Biotech stock?

Here are some recent quotes from research analysts about Krystal Biotech stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating though are lowering our price target to $32 from $35.50. The driver to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count off of October 2018 equity raise; and (3) adjusting our applied P/E multiple from 14.5x to 17.0x, which is our standard multiple in our coverage universe. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (11/5/2018)
  • 2. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (10/17/2018)
  • 3. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and increasing our price target to $35/share from $28/share on Krystal Biotech. This morning, Krystal announced and held a conference call to discuss interim results from two patients in the ongoing Phase 1/2 study (GEM) of KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). The trial met all primary efficacy endpoints for the two patients and showed substantial improvements in time to wound closure, in our view. Importantly, KB103 was well tolerated with no serious adverse events or product- related adverse events reported. Krystal remains on track to complete the study in 1H19." (10/15/2018)
  • 4. Chardan Capital analysts commented, "We note the addition of Mr. Maheu is in line with Krystal’s commitment to establishing in-house manufacturing capabilities. The company confirmed its cGMP facility is on target to be completed by 4Q18, which is in line with previous guidance. Krystal has previously indicated it expects the facility to become operational in 1Q19. The phase I/II trial (NCT03536143) of KB103 in dystrophic epidermolysis bullosa is also on track, with 2 patients currently enrolled. The company affirmed this trial will read out both safety and efficacy data in 4Q18. Additionally, Krystal held a pre-IND meeting with the FDA to discuss its 2nd asset, KB105, in TGM-1-deficient autosomal recessive congenital ichthyosis. As previously stated, the company plans to file the IND in 4Q18. We see continued execution on guidance to be a positive for Krystal." (8/6/2018)
  • 5. William Blair analysts commented, "We anticipate a catalyst rich second half of the year for the company with interim safety and efficacy results from the Phase I/II DEB trial and an IND filing for KB105 in the fourth quarter . In addition, Krystal continues to focus on manufacturing with the completion of a GMP facility for clinical grade products anticipated in the fourth quarter as well as the recent hiring of a vice president of process development and manufacturing operations with Imlygic experience, Amgen’s (AMGN $199.22; Market Perform) HSV-1-based product approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery (backbone similarity to Krystal’s ST AR-D platform)." (8/6/2018)

Has Krystal Biotech been receiving favorable news coverage?

Headlines about KRYS stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Krystal Biotech earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are some of Krystal Biotech's key competitors?

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the folowing people:
  • Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 53)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
  • Ms. Pooja Agarwal, VP of Product Devel. (Age 39)
  • Mr. Antony A. Riley, Chief Financial Officer (Age 51)

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.48%), Baker BROS. Advisors LP (0.79%), S Squared Technology LLC (0.37%), Renaissance Technologies LLC (0.35%), JPMorgan Chase & Co. (0.25%) and JPMorgan Chase & Co. (0.33%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Baker BROS. Advisors LP. View Insider Buying and Selling for Krystal Biotech.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including S Squared Technology LLC, Renaissance Technologies LLC, P.A.W. Capital Corp, JPMorgan Chase & Co., JPMorgan Chase & Co. and Acadian Asset Management LLC. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $20.71.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $313.25 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.

MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by Staff

Featured Article: How is inflation measured?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel